Phreesia, Inc. (NYSE:PHR) General Counsel Sells $143,672.40 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 6,024 shares of the business’s stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $23.85, for a total value of $143,672.40. Following the sale, the general counsel now owns 143,830 shares in the company, valued at approximately $3,430,345.50. This trade represents a 4.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Phreesia Price Performance

PHR stock traded down $1.11 during midday trading on Thursday, reaching $24.09. The company had a trading volume of 639,829 shares, compared to its average volume of 434,457. The firm has a 50-day moving average price of $26.66 and a 200-day moving average price of $24.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The company has a market capitalization of $1.42 billion, a P/E ratio of -16.39 and a beta of 0.82. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $30.53.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PHR shares. Robert W. Baird lowered their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. KeyCorp upped their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Piper Sandler reiterated an “overweight” rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $31.33.

Institutional Investors Weigh In On Phreesia

A number of large investors have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. grew its holdings in shares of Phreesia by 381.3% during the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after purchasing an additional 896 shares during the last quarter. R Squared Ltd purchased a new position in shares of Phreesia in the fourth quarter worth about $30,000. BankPlus Trust Department bought a new stake in shares of Phreesia in the 4th quarter valued at about $34,000. Quarry LP boosted its holdings in Phreesia by 210.9% during the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock valued at $71,000 after acquiring an additional 1,923 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Phreesia during the 4th quarter worth approximately $76,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.